108 related articles for article (PubMed ID: 8856307)
1. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer.
Marinaccio M; D'Addario V; Serratì A; Pinto V; Cagnazzo G
Eur J Gynaecol Oncol; 1996; 17(4):286-8. PubMed ID: 8856307
[TBL] [Abstract][Full Text] [Related]
2. No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm S
Gynecol Oncol; 2002 Sep; 86(3):297-301. PubMed ID: 12217751
[TBL] [Abstract][Full Text] [Related]
3. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
Fishman A; Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Kaplan AL; Girtanner RE; Kavanagh JJ
J Reprod Med; 1996 Jun; 41(6):393-6. PubMed ID: 8799913
[TBL] [Abstract][Full Text] [Related]
4. No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm A
Eur J Cancer; 2002 Nov; 38 Suppl 6():S73. PubMed ID: 12409084
[No Abstract] [Full Text] [Related]
5. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.
Foster KI; Flores Legarreta A; Kamat R; Handley KF; Glassman D; How JA; Lawson BC; Westin SN; Ramondetta LM; Frumovitz M; Gershenson DM; Sood AK; Hillman RT
Am J Obstet Gynecol; 2023 Jun; 228(6):724.e1-724.e9. PubMed ID: 36907533
[TBL] [Abstract][Full Text] [Related]
6. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
Tay SK; Thilagam MD
Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapy of advanced ovarian cancer with GnRH analogs.
Balbi G; Piano LD; Cardone A; Cirelli G
Int J Gynecol Cancer; 2004; 14(5):799-803. PubMed ID: 15361187
[TBL] [Abstract][Full Text] [Related]
8. Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report.
Tresukosol D; Kudelka AP; Edwards CL; Silva EG; Kanojia M; Kavanagh JJ
J Reprod Med; 1996 May; 41(5):363-6. PubMed ID: 8725765
[TBL] [Abstract][Full Text] [Related]
9. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
11. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
12. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.
Karagol H; Saip P; Uygun K; Caloglu M; Eralp Y; Tas F; Aydiner A; Topuz E
Med Oncol; 2007; 24(1):39-43. PubMed ID: 17673810
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
15. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
16. Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Massad LS; Wagley E; Winkelman L; Lincoln S; Yordan EL; de Geest K; Wilbanks GD
Eur J Gynaecol Oncol; 1994; 15(5):337-42. PubMed ID: 7828601
[TBL] [Abstract][Full Text] [Related]
17. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of leuprolide in advanced/recurrent endometrial cancer.
Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
Gynecol Oncol; 1997 Jan; 64(1):126-9. PubMed ID: 8995560
[TBL] [Abstract][Full Text] [Related]
19. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
du BA; Meier W; Lück HJ; Emon G; Moebus V; Schroeder W; Costa S; Bauknecht T; Olbricht S; Jackisch C; Richter B; Wagner U
Ann Oncol; 2002 Feb; 13(2):251-7. PubMed ID: 11886002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
